ABCG2

Broad substrate specificity ATP-binding cassette transporter ABCG2 · Q9UNQ0 · ABCG2 on Sugi Atlas →

268,008 patent compounds predicted against ABCG2, 147,131 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Cromolyn (SCHEMBL3865)	0.47	9/20
Cromolyn (SCHEMBL8199)	0.47	9/20
Cromolyn (SCHEMBL7500)	0.46	9/20
SCHEMBL26321	0.53	6/20
SCHEMBL8920	1.00	5/20
Pachypodol (SCHEMBL39280)	1.00	5/20
Beta-Naphthoflavone (SCHEMBL43538)	1.00	5/20
Xanthoxylin (SCHEMBL44708)	0.62	5/20
Chrysin (SCHEMBL44474)	1.00	4/20
Rhamnazin (SCHEMBL39443)	0.80	4/20
Saperconazole (SCHEMBL65701)	0.79	4/20
Itraconzole (SCHEMBL65702)	0.79	4/20
Dioxybenzone (SCHEMBL15894)	0.56	4/20
Trimebutine (SCHEMBL67225)	0.42	4/20
Kaempferol (SCHEMBL18817)	1.00	3/20
Apigenin (SCHEMBL19428)	1.00	3/20
Morin (SCHEMBL19984)	1.00	3/20
Luteolin (SCHEMBL20426)	1.00	3/20
Itraconazole (SCHEMBL23934)	1.00	3/20
Itraconazole (SCHEMBL23935)	1.00	3/20

Clinical trials — most relevant to ABCG2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Digoxin Dosing in Heart Failure: A Simplified Nomogram Versus Standard Care	PHASE4	COMPLETED
Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation	PHASE1/PHASE2	UNKNOWN
Therapy for Children With Neuroblastoma	PHASE2	COMPLETED
HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer	PHASE2	RECRUITING
The Effect of Perioperative Ketamine on Acute and Chronic Pain After Major Back Surgery	PHASE2	COMPLETED
Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer	PHASE2	COMPLETED
Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC	PHASE2	RECRUITING
Drug Cocktail Interaction Study of St. John's Wort Dry Extract Ze 117	PHASE1	COMPLETED
Influence of Ethnicity and ABCB1 Gene Polymorphism on the Pharmacokinetics of Azithromycin in Healthy Bangladeshi Volunteers	PHASE1	UNKNOWN
mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme	PHASE1	COMPLETED
Indenoisoquinoline LMP400 for Advanced Solid Tumors and Lymphomas	PHASE1	COMPLETED
Drug-drug Interaction Study in Healthy Male Volunteers Following the Administration of Pantoprazole and Rosuvastatin	PHASE1	COMPLETED
Identification and Validation of Biomarkers for Breast Cancer Resistance Protein (BCRP)	PHASE1	COMPLETED
Icotinib Hydrochloride in Treating Patients With Advanced Cancers	PHASE1	WITHDRAWN
A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/Cobicistat	PHASE1	COMPLETED
Validation Study of Multiple Probe Compounds for Drug Interaction Evaluation	PHASE1	COMPLETED
Pharmacokinetic Study to Characterize Individual Metabolic Profile	PHASE1	COMPLETED
Drug-Drug Interaction of Rifampicin and Cyclosporine on Methotrexate Pharmacokinetics in Healthy Subjects	PHASE1	ACTIVE_NOT_RECRUITING
Relative Bioavailability of a Single-dose Administration of BIBW 2992 and Multiple-dose Administration of Ritonavir in Healthy Volunteers	PHASE1	COMPLETED
Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters	EARLY_PHASE1	COMPLETED
Assessing Goldenseal-drug Interactions Using a Probe Drug Cocktail Approach	EARLY_PHASE1	COMPLETED
Effectiveness of Raltegravir-Based Antiretroviral Therapy in HIV-HCV Coinfected Liver Transplant Recipients	nan	COMPLETED
Impact of Polymorphisms of OAT1, OAT3, and OCT2 on Transportation of Potential Nephrotoxic Drugs	nan	COMPLETED
Role of Gene Variation in Effectiveness of Gleevec Treatment	nan	COMPLETED
Moringa Oleifera- Antiretroviral Pharmacokinetic Drug Interaction	nan	COMPLETED
the Effect of ABCC2 Genetic Polymorphism on Neurotoxicity in Gastrointestinal Cancer Patients Receiving Oxaliplatin	nan	UNKNOWN
A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment	nan	RECRUITING
Pharmacogenomics of New Antiretrovirals	nan	COMPLETED
Individualized Antiretroviral Therapy	nan	COMPLETED
Impact of Genetics on Metformin Pharmacokinetics	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a ABCG2 binder may also engage these)

Protein	Name	Similarity
Q8MIB3	—	1.000	Q8MIB3 →
Q5MB13	—	1.000	Q5MB13 →
Q7TMS5	—	0.998	Q7TMS5 →
Q4GZT4	—	0.993	Q4GZT4 →
Q80W57	—	0.989	Q80W57 →
GRM8	Metabotropic glutamate receptor 8	0.931	landscape →
P98200	—	0.927	P98200 →
P47743	—	0.927	P47743 →
P70579	—	0.925	P70579 →
Q7Z2H8	—	0.924	Q7Z2H8 →
Q68ED2	—	0.923	Q68ED2 →
C7EXK4	—	0.923	C7EXK4 →
P70704	—	0.921	P70704 →
Q5RDQ8	—	0.921	Q5RDQ8 →
P35400	—	0.919	P35400 →
GRM7	Metabotropic glutamate receptor 7	0.916	landscape →
E1C6Q1	—	0.914	E1C6Q1 →
Q9NTI2	—	0.914	Q9NTI2 →
Q9Y2Q0	—	0.914	Q9Y2Q0 →
Q3V1L4	—	0.912	Q3V1L4 →
Q14409	—	0.910	Q14409 →
O70152	—	0.910	O70152 →
Q4R4D5	—	0.908	Q4R4D5 →
Q9WU65	—	0.908	Q9WU65 →
GABRA6	Gamma-aminobutyric acid receptor subunit alpha-6	0.907	landscape →
E2R222	—	0.907	E2R222 →
Q64516	—	0.907	Q64516 →
Q29449	—	0.907	Q29449 →
O43502	—	0.906	O43502 →
GK	Glycerol kinase	0.906	landscape →